Insilico Medicine and Servier reach the first milestone in their AI-driven oncology collaboration

Insilico Medicine announced it reached the early drug-discovery milestone in its multi-year AI-driven collaboration with Servier (up to $888 million, $32 million upfront and near-term): two oncology programs started on challenging targets with Insilico's Pharma.AI platform, both completed target nomination, and the first milestone triggers an undisclosed payment from Servier. Company release dated 20 October 2026 (trade press coverage on 29 October).